Europe PMC
metadata only
CC BY 4.0
The impact of DXA findings on general practitioners’ decision regarding first-line oral bisphosphonates in postmenopausal osteoporosis—data from French General Practice (the IMOGENE study)
abstract available
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation#810195
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women#883574
- A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo#1009134
- The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis#1088407
- MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis#836648
Record · ID 1053107
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive